Uexküll & Stolberg – Germany 2022
This traditional Hamburg patent attorney firm is strongly positioned for litigation involving life sciences patents. Well-known clients from the pharma, biotech and chemicals sectors put their faith in the team for extensive EPO oppositions and nullity suits. The patent attorneys often provide technical advice in infringement suits alongside law firms. One example is the dispute for Amgen regarding cinacalcet (with Rospatt Osten Pross). The team was recently busy for Amgen and BMS in large-scale EPO oppositions with numerous opponents. The firm also made steady progress across a wide spectrum of technologies with new portfolios for long-time clients like H&T Presspart and Duracell. The long-established Hamburg firm is continuously investing in developing new talent. This is paying off, as shown by the several young chemists who recently qualified as patent attorneys.
Litigation with a technical focus on pharmaceuticals, biotech and chemicals.
This traditional patent attorney outfit is well positioned for the UPC regarding pharma disputes, as it already boasts extensive litigation experience in the life sciences field. Some of those German cases are also part of pan-European battles between innovators and generic drug companies over blockbuster drugs, as is the case with Amgen and BMS/Pfizer. With its setup as a national patent attorney firm, Uexküll & Stolberg is also an attractive cooperation partner for similar firms from other European jurisdictions that have no interest in establishing their own prosecution practice in Germany.
Albrecht von Menges (“top for biotech”, competitor), Peter Franck, Ulrich-Maria Gross, Heinz-Peter Muth (“very well prepared”, competitor; all patent attorneys)
19 patent attorneys
All-round IP practice focusing on patent prosecution with broad technical expertise. Opposition and nullity suits. Infringement proceedings with external litigators.
Litigation: Amgen (defendant) against Teva, Accord, Glenmark and Biogaran over cancer drug cinacalcet (public knowledge); Amgen (defendant) against Regeneron/Sanofi in EPO opposition over Dupixent (settled 2022); BMS and Pfizer (defendant) against Teva, Stada, Galenicum Generics in EPO opposition over blood anticoagulant apixaban; Bigben (claimant) against Nintendo over consumer electronics (settled 2021); Ivoclar (defendant) against Vita Zahnfabrik over lithium silicate glass ceramic; W.R. Grace (defendant) against Basell in EPO opposition over polyolefine patent. Prosecution: filing and oppositions for ABB, Bayer/Monsanto, W. R. Grace, Chr. Hansen, KRKA, Ohly. Filing for Beiersdorf, Cryovac, Delta Electronics, Duracell, Exxon, Helmholtz-Zentrum, Ivoclar, Microjet Technology, Qiagen, Presspart, Sealed Air (all public knowledge).